Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by the progressive obstruction of the distal pulmonary arteries (PA). Structural and functional alteration of pulmonary artery smooth muscle cells (PASMC) and endothelial cells (PAEC) contributes to PA wall remodeling...
Main Authors: | Malik Bisserier, Michael G. Katz, Carlos Bueno-Beti, Agnieszka Brojakowska, Shihong Zhang, Sarah Gubara, Erik Kohlbrenner, Shahood Fazal, Anthony Fargnoli, Peter Dorfmuller, Marc Humbert, Akiko Hata, David A. Goukassian, Yassine Sassi, Lahouaria Hadri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/17/9105 |
Similar Items
-
BMPR2 expression is suppressed by signaling through the estrogen receptor
by: Austin Eric D, et al.
Published: (2012-02-01) -
Compound BMPR2 gene mutations in a malignant variant of idiopathic pulmonary arterial hypertension
by: Walter Serra, et al.
Published: (2014-12-01) -
Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis
by: Xiaoyue Ge, et al.
Published: (2020-02-01) -
Examining the effects of SERCA2a acetylation in the heart
by: Susser, Shanel
Published: (2016) -
SERCA2a TRANSMEMBRANE MICROPEPTIDES-REGULATORS (LITERATURE REVIEW)
by: A. A. Bolotskaya, et al.
Published: (2020-12-01)